Study drug for depression that didn’t improve on common antidepressants
Part of Mental health clinical trials.
This Phase 2 trial tests OSU6162 added to an SSRI or SNRI in people whose major depression did not improve enough after trying specific antidepressants for at least 6 weeks. It may help reduce depression symptoms when standard treatments haven’t worked well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent and are 25–65 years old at screening.
- You have a diagnosis of major depressive disorder, confirmed by a structured interview.
- Your depression has not significantly improved after at least 6 weeks on one of these: citalopram, escitalopram, paroxetine, sertraline, fluoxetine, duloxetine, or venlafaxine.
- Your current depression severity is at a specific level (MADRS score 22 or higher).
- If you can get pregnant, you must have a negative pregnancy test and use reliable birth control during the study and follow-up.
- You must be willing to avoid certain medicines and stay on stable doses (no major dose changes in the last 4 weeks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called ACP-211 in adults with major depression who have not gotten enough relief from at least two previous antidepressants. The goal is to see if it can help when other treatments have not worked well.
This study tests an investigational medication (CYB003) for people with major depression whose current antidepressant isn't working well enough. It looks at whether this treatment can help improve depression symptoms.
This trial tests whether OSU6162 can improve depressive symptoms in adults with bipolar depression who are already taking a stable mood-stabilizing medicine. It also checks safety by closely monitoring mood, heart rhythm, and other health factors during the study.
This trial tests an investigational drug called NBI-1065845 added to your current antidepressant. It is for people with moderate to severe depression or persistent depressive disorder who have not improved enough with oral antidepressants alone.
This trial tests an investigational medication called ammoxetine for people with moderate to severe depression. It aims to see if the drug can reduce depressive symptoms and is for those who haven't had success with certain other antidepressants.
This trial tests a new medication called NBI-1065845 added to your current antidepressant for people with depression that hasn't fully responded to treatment. It aims to see if this combination can better improve your symptoms.
Hear when a new Depression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.